Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. (2021)

First Author: Barrett JR
Attributed to:  nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19 funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41591-021-01372-z

PubMed Identifier: 33958800

Publication URI: http://europepmc.org/abstract/MED/33958800

Type: Journal Article/Review

Volume: 27

Parent Publication: Nature medicine

Issue: 6

ISSN: 1078-8956